You just read:

Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium

News provided by

Sierra Oncology

Nov 15, 2018, 05:00 ET